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ABSTRACT
Despite the development of new antineoplastic agents for the treatment of 
colorectal cancer (CRC), oxaliplatin and fluoropyrimidines remain the most commonly 
employed drugs for the treatment of both early and advanced disease. Intrinsic or 
acquired resistance is, however, an important limitation to pharmacological therapy, 
and the development of chemosensitization strategies constitute a major goal 
with important clinical implications. In the present work, we determined that high 
levels of activated Src kinase, measured as phospho-Src at the Tyr419 residue in 
CRC cell lines, can promote colorectal carcinoma cell resistance to oxaliplatin, but 
not to 5-fluorouracil (5FU), and that inhibition of this protein restores sensitivity to 
oxaliplatin. Similar results were observed with in vivo patient-derived xenograft (PDX) 
models that were orthotopically grown in murine livers. In PDX tumor lines derived 
from human CRC liver metastasis, dasatinib, a Src inhibitor, increases sensitivity 
to oxaliplatin only in tumors with high p-Src. However, dasatinib did not modify 
sensitivity to 5FU in any of the models. Our data suggest that chemoresistance 
induced by p-Src is specific to oxaliplatin, and that p-Src levels can be used to identify 
patients who may benefit from this combination therapy. These results are relevant 
for clinicians as they identify a novel biomarker of drug resistance that is suitable to 
pharmacological manipulation.
INTRODUCTION
Metastatic CRC (mCRC) remains incurable for 
patients with surgically unresectable disease. Several 
combination regimens including fluoropyrimidines, 
oxaliplatin and/or irinotecan, with or without monoclonal 
antibodies targeting vascular endotelial growth factor 
(VEGF) or epidermal growth factor receptor (EGFR), 
remain the mainstay of care in metastatic CRC (mCRC). 
Response rates, however, are observed in only 40–60% 
of the patients, and even responding patients inevitably 
develop refractory disease, with median overall survival 
that does not generally exceed 2-2,5 years.
Oxaliplatin, one of the most commonly used 
drugs in the treatment of CRC, is a platinum-based 
chemotherapeutic agent that forms platinum-DNA adducts 
that block DNA replication, leading to cell cycle arrest 
and cell death [1–4]. Resistance to platinum agents occurs 
Oncotarget33112www.impactjournals.com/oncotarget
through several mechanisms, including decreased platinum 
influx, improved base excision repair, and/or increased 
detoxification by glutathione and metallothionein [1, 3]. 
Reversing resistance has proved to be challenging, due in 
part to ineffective pharmacological modulation of these 
pathways. Recently, however, Src family kinases have been 
implicated in drug resistance [5, 6]. Src is the prototype of 
this nine-member family, and it is activated by numerous 
growth migratory, and stress pathways [7]. In CRC cell 
lines and primary tumors, both c-Src kinase activity and 
protein expression levels have been found to be elevated 
compared with either normal colonic mucosal cells and 
fibroblasts or normal adjacent tissue [8–10]. However, 
c-Src seems to experience a robust increase in expression 
and activity in CRC liver metastases compared with 
metastases derived from other tumors types [11, 12], and 
increased c-Src levels correlate with worse patient survival 
[13]. The Src proteins belong to a family of non-receptor 
cytoplasmic protein tyrosine kinases that act as signaling 
complexes, which recruit and participate in intracellular 
signal transduction pathways related to carcinogenesis, as 
well as cell proliferation and differentiation, angiogenesis, 
migration, invasion, adhesion and apoptosis [14–16]. 
Phosphorylation and dephosphorylation regulate Src 
activity. In its inactive form, the end carboxyl-terminal 
Tyr527 residue is phosphorylated by protein tyrosine 
kinase Csk. Dephosphorylation at this level induces 
a conformational change in the protein, allowing the 
autophosphorylation of Tyr at residue 419, which is present 
in the activation loop, promoting and activating Src kinase 
(p-Src) [17, 18]. In normal basal conditions, 90-95% of Src 
es found in its inactive conformation. However, mutations 
at residue Tyr527 and the SH2 and SH3 domains, or 
alterations in Csk kinase activity, lead to constitutively 
activated p-Src. Whereas Src has been implicated in a 
myriad of cellular processes that are deregulated in cancer, 
current evidence suggests that Src activation is critical 
to tumor progression and metastasis [16]. In CRC, Src 
deregulation primarily involves protein overexpression, 
although the molecular mechanisms have not been 
fully elucidated. In addition, evidence from preclinical 
studies in sarcoma and ovarian cancer cell lines suggests 
that activation of Src reduces sensitivity to various 
chemotherapeutic drugs, including platinum agents, and 
that this resistance can be reversed by pharmacological 
inhibition [19, 20][21–23][24]. For example, treatment 
with the Src inhibitor PP2 reversed cisplatin resistance in 
a multidrug-resistant ovarian carcinoma cell line compared 
with its isogenic control [25]. Moreover, expression of a 
dominant negative, kinase-defective Src mutant resulted 
in increased sensitivity to oxaliplatin-mediated apoptosis 
in KM12L4 human colon tumor cells in vitro [21]. As a 
result, coupled with the recent availability of relatively 
non-toxic Src family inhibitors, numerous clinical trials 
have been initiated to evaluate small molecule Src family 
inhibitors in solid tumors [24, 26].
The overall objective of our work is to evaluate the 
effect of Src inhibition in vivo and correlate effective Src 
inhibition with a biomarker that can be used in patients. 
With this purpose, we first explored the expression 
of p-Src in CRC cell lines and assessed its role as a 
predictor of resistance to currently used therapies. We also 
investigated the use of Src inhibitors as chemosensitizers 
to these therapies in vitro and in patient-derived 
xenografts, PDX, and compared the efficacy with p-Src 
activation in these tumors. Predicting the tumors in which 
Src inhibition may be a valuable addition to oxaliplatin-
based chemotherapeutic regimens, and understanding the 
mechanisms by which this occurs shall provide clinicians 
useful tools to improve the identification of patients who 
may benefit from Src inhibitors.
RESULTS
Effect of oxaliplatin in a panel of CRC cell lines
To explore the effect of Src activation, we evaluated 
a panel of 8 colorectal carcinoma cell lines (Table 1, 
Suplementary Table S1). We first characterized the levels 
of active Src (Src protein phosphorylated at Tyr419, 
p-Src) and correlated this activation with downstream 
pathway effectors. We observed that 4 cell lines carry 
activated Src, p-Src, COLO205, HT29, LS174T and 
LS180. The remaining cell lines, LOVO, SW48, SW480 
and T84, do not contain activated Src. The high levels of 
p-Src correlated with increased levels of total Src protein 
and maintained high levels of activated p42MAPK 
(Figure 1A). We also observed that p42MAPK activation 
correlated with p-Src but did not correlate with mutant Ras 
or Raf in these cell lines (Figure 1A).
Next, we treated the 8 CRC cell lines with 
different concentrations of oxaliplatin and obtained an 
IC50 for each cell line. The response rankings from low 
concentrations to concentrations higher than 100 μM, as in 
HT29 and LS180 are shown in Table 1. The IC50 values 
of each cell line were influenced by level of activated Src 
(SrcY419), with higher levels observed in chemoresistant 
cell lines as shown in Figure 1B. Values were also 
influenced by the levels of phosphorylated p42MAPK. 
However, the number of cell lines explored was too small 
to draw definitive conclusions. COLO-205 does not show 
oxaliplatin resistance despite expressing high levels of 
p-Src.
Src overexpression induces chemoresistance to 
oxaliplatin in CRC cell lines
Although we examined a limited number of cell 
lines, which may limit the relevance of our findings, 
we constitutively overexpressed the c-Src gene to study 
the functional relationship between p-Src levels and 
cellular responses to oxaliplatin [27]. We performed 
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SW48 1.47 ± 0.4
SW480 5.50 ± 1.6
LoVo 8.29 ± 4.4
T84 8.20 ± 1.4
COLO-205 6.43 ± 1.2
LS174-T 29 ± 2.4
HT-29 100 ± 2.1
LS180 616 ± 6.2
Figure 1: A. Characterization of the levels of phospho-Src in the CRC cell lines used in this study. Western blots were performed to 
measure p-Src, Src and p42/p44 MAPK protein levels. B. The cytotoxic effects of oxaliplatin directly correlate with activated Src protein 
levels. (a) IC50 values are separated in two differentiated groups by Src levels. (b) IC50 values without SD are grouped into a fall plot 
representation. C. Overexpression of c-Src in CRC cell lines induces activation of the pathway. Western blot analysis was performed to 
evaluate Src protein (anti-Src), the activated form of Src kinase (phosphorylated SrcY419), and p42/p44 Map kinase in CRC cell lines 
with normal endogenous expression of Src and overexpression of Src through stable transfection (T84 and SW480). D. Src inhibitor PP2 
inhibits Src activity. Western blotting was performed to evaluate Src protein (anti-Src), the activated form of Src kinase (phosphorylated 
SrcY419), and p42/p44 Map kinase in CRC cell lines with normal endogenous expression of Src and overexpression of Src through stable 
transfection (T84 and SW480).
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this evaluation in 2 different CRC cell lines with low 
levels of endogenous p-Src, T84 and SW480 (Figure 
1C, Supplementary Figure S1). We observed that c-Src 
overexpression led to activation of p-Src in these cell 
lines, with concurrent activation of MAPKs (Figure 1C), 
correlating with the previous observation (Figure 1A). 
Furthermore, the pharmacological inhibition of p-Src with 
a PP2 inhibitor [28, 29] causes MAPK inhibition in these 
cell lines (Figure 1D). These data seem to confirm that the 
activation of MAPKs in CRC cell lines is more dependent 
on p-Src levels than on Ras or Raf mutations.
To gain insight into the effect of p-Src activation on 
cell line survival in the presence of oxaliplatin, we treated 
these p-Src transfected cells lines with oxaliplatin. We 
observed that cell lines expressing high p-Src had a two-
fold higher IC50 compared with parental cells expressing 
an empty vector (Table 2). However, the IC50 values 
did not reach the levels of other resistant cell lines, such 
as HT29. On the other hand, treatment with PP2 alone 
is not sufficient to induce high toxicity in these cells 
independent of the levels of p-Src (Table 2). Finally, in 
response to the combination with sublethal doses of PP2, 
cells overexpressing p-Src were resensitized to oxaliplatin 
(Table 2).
Because CRC patients are also treated with 5FU 
[30], we explored whether p-Src is also relevant to the 
in vitro response to this drug. The same cell lines were 
treated with 5FU, and their IC50s were calculated. We 
did not find a clear correlation between responses to 
this drug and p-Src levels, even in cells overexpressing 
p-Src (Table 3). In fact, inhibition of p-Src by PP2 did not 
clearly sensitize the cells to 5FU treatment (Table 3).
Our data suggest, therefore, that the chemoresistance 
induced by p-Src is specific to oxaliplatin.
Table 2: Activation of Src induces chemoresistance to Oxaliplatin 
Transfectant
IC50 (μM)
Ras/Raf status PP2 Oxaliplatin Oxaliplatin + PP2 *
SW480 Mutated Ras 18,75 ± 3,2 5.50 ± 1.6 1.23 ± 1.3
SW480 SRC Mutated Ras 15,58 ± 4,7 10.44 ± 2.3 3.29 ± 1.0
T84 Mutated Ras 13,42 ± 2,8 8.20 ± 1.4 1.8 ± 2.2
T84 SRC Mutated Ras 15,58 ± 4,7 14.75 ± 2.1 6.39 ± 1.7
HT-29 Mutated Raf 10,23 ± 4,5 100 ± 2.1 8.97 ± 1.1
*IC50 of oxaliplatin was calculated at constant concentration of 10 microM PP2.
Chemosensitization to Oxaliplatin was observed through the addition of Src inhibitor PP2.
Table 3: Colorectal adenocarcinoma cell line chemosensitivity to 5 Fluorouracil (5FU)
IC50 (μM)
Transfectant 5-Fu PP2 5-Fu + PP2
SW48 16,1 ± 3,2 14,78 ± 3,6 16,4 ± 4,4
SW480 21,5 ± 3,4 18,75 ± 3,2 17,3 ± 2,4
SW480 SRC 25,1 ± 2,1 15,58 ± 4,7 12 ± 4,1
LoVo 17 ± 2,3 14,21 ± 3,3 18,5 ± 3,6
T84 19,3 ± 4,6 13,42 ± 2,8 9,8 ± 4,3
T84 SRC 12,7 ± 4,1 13,78 ± 3,5 7,3 ± 3,7
COLO-205 8,9 ± 1,6 12,88 ± 3,4 9,2 ± 2,4
LS174-T 27,42 ± 3,6 18,61 ± 4,2 23,47 ± 4,8
HT-29 23,9 ± 4,5 10,23 ± 4,5 8,7 ± 2,3
LS180 3,69 ± 1,7 16,41 ± 5,7 4,5 ± 2,6
*IC50 of 5FU was calculated at constant concentration of 10 microM PP2.
Oncotarget33115www.impactjournals.com/oncotarget
In vivo Src inhibition of liver metastasis of 
colorectal tumors
To explore the effect of Src inhibition in vivo, we 
used orthotopic PDX models that were generated from 
mCRC patients undergoing surgical resection of liver 
metastasis. Twenty-six tumor samples derived from these 
CRC liver metastases were surgically implanted into 
the livers of female nude mice (nu/nu) aged 4-6 weeks 
according to the protocol described in the Materials and 
Methods section. Of the 26 tumors implanted, 42% grew 
and were reimplanted according to a procedure that was 
identical to that used for primary sample placement. In 
all cases, we observed tumor growth in the liver (Figure 
2A). PDXs grow orthotopically in the liver, maintaining 
the same architecture and histological features of the 
human metastasis from which they were derived (Figure 
2B and 2C).
The molecular profile, including the analysis of 
Ras, Raf, PI3K or PDGFR mutations, and microsatellite 
instability (MSI), also showed identical behavior in the 
human and PDX models (data not shown).
From this panel, we selected 4 PDX lines (Figure 3), 
two with high p-Src and two with low p-Src expression. 
One model, C13, which had low p-Src expression, lacked 
mutations in Ras, Raf, PI3K, PDGFR, and had not MSI 
(Figure 3), whereas C18, which had also low p-Src 
expression, had mutations in Ras and PI3Ka and lacked 
mutations in Raf and MSI. On the other hand, both models 
with high p-Src expression, C35 and C36, had mutations 
in Ras and lacked mutations in Raf. C36 also showed 
activating mutations in PI3Ka.
The four liver metastases of CRC tumor-derived 
PDXs were orthotopically engrafted into murine liver 
and grown for 15 days to ensure proper engraftment. 
One mouse from each cohort was sacrificed to examine 
tumor engraftment (Figure 4A). Then, the animals were 
treated with oxaliplatin, the p-Src inhibitor dasatinib, a 
combination of both drugs (oxaliplatin plus dasatinib) or 
solvent (untreated control). On the day after the final dose, 
one mice harboring each tumor subtype that were treated 
with solvent or any of the treatments were sacrificed, and 
their tissues were analyzed for the expression of p-Src in 
the liver. We found a clear effect of p-Src inhibition in the 
livers of mice treated with dasatinib (Figure 4B).
To explore the effects of different treatments on 
these tumors, we treated for 4 weeks with oxaliplatin, 
the p-Src inhibitor dasatinib, a combination of both drugs 
(oxaliplatin plus dasatinib) or solvent (untreated) and 
then analyzed the survival of these mice (Figure 5A). We 
observed that the survival curves of mice carrying PDX 
tumors were not significantly different between untreated 
mice and mice treated with oxaliplatin or dasatinib alone. 
These results were independent of the levels of p-Src in 
each model. However, we observed clear and statistically 
significant improvement in the survival of mice with high 
p-Src that were treated with a combination of oxaliplatin 
plus dasatinib (Figure 5A). This improved survival was 
not observed in mice with low p-Src expression.
The analysis of tumor size at various end points 
indicated a similar, albeit heterogeneous, size for all 
tumors (Figure 6), suggesting that survival was determined 
by tumor growth.
Of note, the increased efficacy of dasatinib plus 
oxaliplatin, as compared to either drug alone, observed 
in mice with CRC liver metastases was specific for 
oxaliplatin. We repeated the experiment with 5FU, another 
drug that is commonly used for late stage CRC tumors 
[31], but no clear improvement in survival was detected in 
mice that were treated with 5FU alone or in combination 
with dasatinib (Figure 5B).
In vivo p-Src inhibition by dasatinib is sinergistic 
with oxaliplatin in treating CRC liver metastasis, 
suggesting that p-Src is a possible biomarker for selecting 
patients who may benefit from this combination therapy.
DISCUSSION
Despite advances in the development of new 
chemotherapeutic agents, advanced colorectal cancers 
remains an essentially incurable disease, as all patients 
eventually develop drug resistance, resulting in disease 
progression and death. Thus, therapeutic strategies that re-
sensitize tumors to these agents may improve outcomes 
[32]. In this work, we demonstrated that one mediator 
of oxaliplatin sensitivity/resistance in some colon tumor 
cells is the active tyrosine kinase, Src. The cytoprotective 
effect of p-Src is specific to oxaliplatin and does not 
affect the tumor cell response to 5FU. Furthermore, p-Src 
(phosphorylated at Tyr419) is a good marker for predicting 
the activity of dasatinib in restoring oxaliplatin sensitivity 
in vivo.
Src activation promotes tumor progression and 
is associated with an aggressive phenotype and a poor 
prognosis in CRC [32]. C-Src kinase activity is balanced 
by the orchestrated function of protein kinases and 
phosphatases that mainly target Tyr530 at the C-terminal 
tail. C-terminal Src kinase (Csk) operates as a negative 
regulator, phosphorylating c-Src at the C-terminal 
segment [33]. Additionally, several cytoplasmic and 
transmembrane protein tyrosine phosphatases (PTPs) 
have been found to dephosphorylate c-Src at Tyr530, 
regulating its kinase activity [34]. Downregulation of 
the transmembrane PTPa has been proven to inhibit Src 
kinase activity and induce apoptosis in CRC cells [35]. 
Moreover, splice mutants of receptor-like PTPa (RPTPa) 
have been detected in 30% of colon, breast and liver 
tumors. Specifically, the expression of the RPTPa245 
mutant in tumors facilitates the activation of Src via 
RPTPa binding [36]. In conjunction with the genetic 
regulation of Src, further epigenetic regulation of Src has 
emerged as an additional factor in CRC tumorigenesis 
Oncotarget33116www.impactjournals.com/oncotarget
Figure 2: A. Three representative examples of CRC liver metastasis growing orthotopically in murine liver. B. and C. Human CRC 
liver metastasis and their derived PDX lines show similar pathological features. B) Hematoxylin and eosin staining and C) cytokeratin 20 
staining of CRC human liver metastasis and their derived PDX lines. In these figures, a/b/c correspond to the human tumors, and a1/b1/c1, 
to the PDX derived tumors.
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Figure 3: Relevant molecular characteristics of the PDX lines used in this study. A western blot with the phospho-Src levels 
and the information about K-Ras, B-Raf, PI3Ka and PDGFRb mutation (M) or wild type (WT). The figure also shows whether (+) or not 
(-) the tumor present microsatellite instability, MSI.
Figure 4: A. Orthotopic engraftment of human CRC liver metastasis in murine livers at the initiation of treatment. The four liver metastases 
of CRC tumor-derived PDXs were orthotopically engrafted into murine liver and grown for 15 days to ensure proper engraftment. One mouse 
from each cohort was sacrificed to examine tumor engraftment. Mice were sacrificed and tumors analyzed. Picture shows representative 
macroscopic tumor engraft growing in liver (arrow) and a micrograph of tumor tissue of the same sample. This was repeated in all cohorts to 
ensure equal engraftment. B. Decrease in the levels of activated p-Src in the livers of treated mice. After 4 weeks of treatment, one mice of 
each cohort was sacrificed and the necropsy done. The liver was fixed and analyzed by immunohistochemistry for efficacy of pSrc inhibition.
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Figure 5: Survival curve of treated murine cohorts. The four liver metastases of CRC tumor-derived PDXs were orthotopically 
engrafted into murine liver and grown for 15 days to ensure proper engraftment. Mice were allocated ad random to conform the cohorts 
and treated for 4 weeks as indicated in M&M. Then, the mice were maintained and observed daily. At signs of distress or illness the mice 
were sacrificed. A. Cohorts of mice treated with solvent alone, oxaliplatin, dasatinib or a combination of dasatinib+oxaliplatin. B. Cohorts 
of mice treated with solvent alone, 5FU, dasatinib or a combination of dasatinib+5FU.
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Figure 6: Size of PDX tumors in all cohorts at endpoint. After sacrifice by humane end-point, all mice were necropsied and the 
tumor growing in liver measured. Each point represents the volume of the tumor found in each mice treated in our experiments.
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[32, 37], including micro-RNAs. C-Src upregulation was 
correlated with miR-542-3p downregulation. Upregulation 
of integrin-linked kinase (ILK) follows, which promotes 
further c-Src and focal adhesion kinase (FAK) activation, 
as well as tumorigenic and invasive potential [38, 39]. 
Whether Src mediates growth factor receptor signaling 
leading to mitogenesis of CRC cells has not been clearly 
demonstrated. Contradictory results show that an elevated 
c-Src level does not directly influence proliferation 
neither in vitro or in vivo in CRC, but it is now accepted 
that c-Src-dependent cell cycle regulation is integrated 
through multiple interactions with membrane receptors 
and their downstream mitogenic signaling pathways 
[14, 16, 27, 40, 41]. It has been described that c-Src 
also enhances resistance to apoptosis by accelerating the 
ubiquination and proteasomal degradation of the protein 
Bcl-2 interacting killer (Bik) via the MAP kinase signaling 
pathway in CRC and lung cancer cells [16, 25, 40].
Dasatinib is a dual oral inhibitor of Src/V-abl 
Abelson murine leukemia viral oncogene homolog (Abl), 
which also targets a number of other Src family kinase 
members and receptor tyrosine kinases (RTKs), such as 
c-kit, PDGFRa, PDGFRb, Ephrin receptors and discoidin 
domain receptor 1 (DDR1). Dasatinib is already approved 
for the treatment of chronic myeloid leukemia and 
Philadelphia chromosomepositive acute lymphoblastic 
leukemia [42]. In CRC cell lines, dasatinib inhibits 
integrin-dependent cell adhesion and migration, with 
parallel inhibition of c-Src activity. Moreover, dasatinib 
has been found to inhibit FAK and paxillin activation 
[42–44]. However, the most relevant finding is the in vivo 
detection of a correlation between the inhibition of c-Src 
activity in peripheral blood mononuclear cells and the 
inhibition of kinase activity in tumors. This observation 
suggests peripheral blood may provide a useful surrogate 
tissue for biomarker studies with dasatinib [45].
To date, Src inhibitors as monotherapy have not 
yielded promising results [46, 47]. However, the use of Src 
inhibitors in combination with cytotoxic chemotherapy or 
RTK inhibitors seems more encouraging. Several early 
clinical trials are currently assessing these combinations 
in advanced solid tumors and metastatic CRC and shall 
provide further insights of this therapeutic approach in the 
near future [20, 32].
Combination therapy with dasatinib and oxaliplatin 
in a CRC metastatic murine model resulted in smaller 
tumors than therapy with either agent alone. Oxaliplatin 
was proven to activate c-Src through a ROS-dependent 
mechanism, and dasatinib-mediated c-Src inhibition 
sensitized cells to oxaliplatin activity [48]. Our in vitro and 
in vivo data showed that Src inhibition is effective only in 
CRC liver metastasis with high p-Src expression at Tyr419, 
which also correlates with an increased activation of 
MAPKs. In metastatic CRC, Kras mutations are predictive 
biomarkers of resistance to cetuximab. However, dasatinib 
has been found to more effectively treat Kras-mutant CRC 
cell lines than cetuximab, and the administration of both 
drugs shows better anti-proliferative effects in vitro and 
in vivo [49]. Consistent with this, the presence of Kras 
mutations in our models is irrelevant to dasatinib-mediated 
chemosensitization to oxaliplatin in vitro and in vivo. 
Reduced SFK activity by molecular and pharmacological 
inhibition also decreases VEGF expression in vitro and 
seems to suppress neo-vascularization in vivo [50][51]
[52]. Based on these observations, it has been postulated 
that dasatinib may prevent increases in plasma VEGF 
during treatment with the VEGF-targeted monoclonal 
antibody bevacizumab, and may thereby enhance the 
effect of anti-angiogenic therapies. Dasatinib is in fact 
currently being tested in combination with capecitabine 
and bevacizumab in previously untreated metastatic CRC 
patients.
At this point we do not know the molecular 
mechanism that precludes dasatinib sensitizing these 
tumors to 5FU. It is possible that a higher level of ROS 
induced by oxaliplatin may influence the response 
by additional activation of Src [48]. This additional 
activation will make these cells yet more dependent on 
Src activity for survival through an oncogenic addiction-
like mechanism.
In summary, dasatinib effectively sensitizes CRC 
liver metastasis to oxaliplatin in orthotopically-grown 
patient-derived xenografts, However, dasatinib has this 
effect only in tumors with high Src phosphorylation at 
Tyr419. As a result, high Src phosphorylation is a good 
prognostic and predictive marker that can be easily tested 
in ongoing clinical trials.
MATERIALS AND METHODS
Human colorectal adenocarcinoma cell lines, 
culture conditions and transfection
COLO-205, SW48, SW480, LS180, LS174-T, 
HT-29, T84 and LoVo cells were purchased from the 
European Collection of Cell Cultures (ECACC). Cells in 
culture were maintained as a subconfluent monolayer in 
Dulbecco’s Modified Eagle’s medium supplied with non-
essential amino acids (LS180 and LS174-T), Dulbecco’s 
modified Eagle’s medium-F12 nutrient mixture (T84), 
McCoy 5-A medium (HT-29), L15 Leivobitz medium 
(SW48 and SW480), Nutrient Mixture F12 HAM (LoVo) 
and RPMI 1640 (Colo-205) purchased from Sigma. Each 
cell line was grown under identical conditions, and cell 
culture medium supplements were provided according to 
the manufacturer’s instructions. To ectopically overexpress 
c-Src kinase protein, subconfluent SW480 and T84 cells 
were transfected with 0.4 μg of pBABE-puro expression 
plasmid carrying cDNA from a c-Src gene. Stable clones 
of the T84 cell line were selected in F12/DMEM medium 
supplied with 0.5 μg of puromycin for 3 weeks. In the 
same way, stable clones of the SW480 cell line were 
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selected in L15 Leivobitz medium supplied with 0.5 μg 
of puromycin. As a control, subconfluent SW480 and T84 
cells were transfected with 0.4 μg of DNA containing an 
empty pBABE-puro expression plasmid. Positive clones 
were selected for protein expression measured by Western 
blotting. The entire set of transfected clones was used as a 
stable pool for transfection.
Western blotting
Cells were washed twice in PBS, lysed in RIPA 
lysis buffer (Tris–HCl pH 8.0 25 mM, NaCl 150 mM, 
NP40 1%, sodium deoxycholate 1%, SDS 1%, Na3VO4 
1 mM, EDTA 0.5 M, and complete protease and 
phosphatase inhibitor cocktail 2 mM) and subjected to a 
3x sonication burst cycle for 5 seconds at 30-40%. The 
cells were ultimately pelleted for 30 seconds at 14000× 
g. After centrifugation, supernatant protein extracts were 
aliquoted and stored at −80°C until use. Protein levels 
were determined by Bradford assay using BSA (bovine 
serum albumin) as a standard. The appropriate protein 
quantity was dissolved in Laemli buffer (Tris–HCl, pH 
6.8, 62.5 mM, glycerol 10%, SDS 1%, 2-mercapto ethanol 
5%, bromphenol blue 0.0025%), and the proteins were 
separated on SDS-PAGE gels (12%) before they were 
blotted onto a nitrocellulose transfer membrane (Whatman 
- Protrans). The primary antibodies included the following: 
anti-Src antibody 1:2500 [EG107] – (Abcam ab32102), 
anti-Src (phospho Y419) antibody – (Abcam ab4816), 
p44/p42 MAPK (Erk1/2) Rabbit mAb 1:1000 (Cell 
Signaling 137F5), and tubulin 1:10000 (Sigma – T6557). 
The secondary antibodies included goat anti-rabbit Alexa 
Fluor 680 1:5000 (Invitrogen – A21057) and donkey anti-
mouse IRDye 800CW 1:5000 (Rockland Inc. – 605-731-
002). To inhibit c-Src, an inhibitor of Src family kinases, 
PP2 (Sigma #P0042-5MG), was supplied at a 10 μM 
concentration overnight before protein extraction.
Cytotoxicity assay
Oxaliplatin, 5-Fluorouracil (5FU) and PP2 (a 
Src inhibitor) were freshly and individually prepared in 
deionized water (Oxaliplatin 10 mM, 5FU 32.09 mM) 
or DMSO (PP2 30 mM) for each experiment. Cell lines 
were seeded in 96-well plates (2.000-3.000 cells per well 
depending on the cell size). The treatment was assayed 
after the application of decreasing concentrations in a 
1:3 fixed ratio to exponential phase growing cells. All 
treatments were applied within decreasing doses of 
Oxaliplatin, 5FU and PP2 individually or in a fixed ratio 
24 hours after seeding. Proliferation was determined by 
MTT assay after 96 hours. Cytotoxicity was measured 
by absorbance at 595 nm using a microplate reader 
(BIORAD iMark™ Microplate Reader); then, the IC50 
was estimated using GraphPad Prism 4 software. For 
combined treatments, PP2 (10 μM) were plated with 
decreasing doses of both Oxaliplatin and 5FU at a fixed 
ratio. Combination indices were obtained by previous 
suboptimal doses of Oxaliplatin, 5FU and PP2 alone.
Human metastatic tumors samples
Tumor samples were collected from patients 
undergoing surgical resection of CRC liver metastasis 
at Hospital Universitario Virgen del Rocío (Seville, 
Spain). All patients previously provided a signed consent 
according to a study protocol approved by the local ethics 
committee (CEI 2012/PI007).
Patient derived xenograft (PDX) generation
Tumor samples derived from colorectal cancer 
liver metastases were resected and freshly collected 
from patients. Then, they were maintained in Dulbecco’s 
modified Eagle’s medium nutrient mixture/F10 (DMEM/
F10 Sigma) containing 10% fetal bovine serum, 
penicillin, streptomycin and amphotericin B (100 mg/
ml each; Sigma). The samples were maintained for less 
than 2 hours in cell culture medium at room temperature 
before orthotopic implantation. Each tissue was divided 
into 2 fragments. One fragment was frozen for further 
molecular analysis, and the remaining tumor sample was 
divided into fragments that ranged from 2-3 mm and 
were eventually used for orthotopic liver implantation in 
6-week-old Foxn1nu athymic nude female mice (Harlan 
Laboratories, Netherlands). The mice were anesthetized 
with ketamine. After laparotomy, an area of 3x3 mm 
was dissected in the anterior side of the left hepatic lobe. 
Inside the dissected cavity human metastasis of CRC was 
implanted. Neoplastic tissue grew inside liver tissue. Six 
months later, all mice were euthanized, and the tumors 
were individually re-implanted and grown in a similar 
setting, allowing experiments within a physiologically 
and molecularly similar setting. These experiments were 
performed according to the European guidelines for 
laboratory animal care. This study was approved by the 
IBIS Institutional Animal Care and Use Committee.
In vivo treatments
Each tumor sample was xenografted individually 
into nude mice. After sufficient tumor growth, the mice 
were euthanized, and their tumors were collected and 
divided onto 2x2x2 mm blocks and then orthotopically 
re-implanted in mice liver. Experiments were performed 
using 6-murine cohorts. Mice were randomly allotted 
to drug-treatment using Oxaliplatin, 5FU, dasatinib, 
solvent and combined treatments. Five weeks after tumor 
implantation, all mice were treated for 4 weeks (2-5 times 
per week depending on the treatment type). Each symptom 
of murine distress was periodically verified twice a week 
and the murine weight was measured at the same time. In 
Oncotarget33122www.impactjournals.com/oncotarget
vivo experiments were completed at a clinical endpoint 
according to the IBIS Institutional Animal Care and Use 
Committee. Oxaliplatin and 5FU were obtained from the 
pharmacy at Hospital Universitario Virgen del Rocío, 
freshly prepared and intraperitoneally administered at 
1 mg/Kg/dose over a period of 4 weeks (twice a week, 
different days). Dasatinib, (BMS-354825) was freshly 
prepared and administered at 20 mg/Kg/dose over a period 
of 4 weeks (5 times per week, on different days).
Necropsy procedures
The experiments were terminated when the animals 
reached a human equivalent end-point. All mice were 
eventually sacrificed and necropsied. Tumors were excised 
and measured using a caliper according to the following 
equation: tumor volume = [length x width2]/2.
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